Inner -City Asthma  Consortium  Confidential  Page  1 of 37 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  INNER -CITY ASTHMA CONSORTIUM  
PROTOCOL  ICAC -26 
A BIOMARKER -BASED  PI[INVESTIGATOR_512016] -SENSITIVE  ADULTS  WITH  ASTHMA  
VERSION 2.0 / January 22, 2016 
IND # Exempt  
Study  Sponsor:  The Division  of Allergy,  Immunology,  and Transplantation,  National  Institute  of Allergy  
and Infectious  Diseases  (NIAID)  
NIAID  Funding  Mechanism:  Grant  [ADDRESS_662275]  HHSN272201000052I  
Stud
y Drug  Manufacturer/Provider :  Greer  Laboratories  
PROTOCOL  CHAIR- ROBERT  WOOD  
Johns  Hopkins  University School  of 
Medicine  
[ADDRESS_662276],  CMSC  1102  
Baltimore,  MD [ZIP_CODE]  
Phone:  (410)  955- 5883  
Fax: (410)  955-0229  
E-mail: [EMAIL_2090]  MEDICAL  MONITOR -PETER  GERGEN  
Division  of Allergy,  Immunology,  and 
Transplantation  
National Institute  of Allergy  and 
Infectious  Diseases  
[ADDRESS_662277],  Room  6B58  
Bethesda  MD [ZIP_CODE],  [LOCATION_003] 
Phone:  (240)  627-3545  
Fax: (301)  480-2381  
E-mail: [EMAIL_2091]  BIOSTATISTICIAN - SAMUEL  ARBES  
Senior  Research Scientist  
Rho, Inc. 
[ADDRESS_662278]. 
Chapel  Hill, NC [ZIP_CODE] 
Phone:  ( 919)  408-8000  
Fax:  (919)  408- 0999  
E-mail:  [EMAIL_9729]  
PROJECT  MANAGER -KATHERINE  THOMPSON  
Division  of Allergy,  Immunology,  and 
Transplantation  
National Institute  of Allergy  and 
Infectious  Diseases  
[PO_BOX] 
Lecanto,  FL [ZIP_CODE],  [LOCATION_003] 
Phone:  (301)  706-1177  
E-mail: [EMAIL_9730]  REGULATORY  OFFICER -LYUDMILA  LYAKH  
Office  of Regulatory  Affairs  
Division  of Allergy,  Immunology,  and 
Transplantation  
National Institute  of Allergy  and 
Infectious  Diseases  
[ADDRESS_662279],  Rm 7B39  
Bethesda  MD [ZIP_CODE],  [LOCATION_003] 
Phone:  (240)  627-3530  
Fax: (301)  480-1537  
E-mail: [EMAIL_2093]   
Confidentiality  Statement  
The information contained  within this  document  is not to be disclosed in  any way  without  the prior permission of the 
Protocol  Chair,  or the Division of Allergy,  Immunology and Transplantation,  National Institute  of Allergy  and Infectious  
Diseases  of the National  Institutes  of Health. 
Inner -City Asthma  Consortium  Confidential  Page  2 of 37 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse   
  
 
 
 
 
 
INVESTIGATOR SIGNATURE [CONTACT_73898]:  ICAC -26 Version/Date:   2.0 / 22 Jan 2016 
Site Principal  Investigator:  
[CONTACT_1641]:  A Biomarker -Based  Pi[INVESTIGATOR_512017]- Sensitive  Adults  with Asthma  and / or Perennial  Allergic  Rhinitis 
Study  Sponsor:   The National  Institute  of Allergy  and Infectious  Diseases  (NIAID) 
INSTRUCTIONS:  The site Principal  Investigator  [INVESTIGATOR_453499],  sign,  and date  at the indicated location  
below.  A copy should be  kept  for your  records  and the original signature  [CONTACT_512073].  After signature,  
please  return  the original  of this form by  [CONTACT_512043]: 
 
DAIT  Regulatory Management  Center  
Pharmaceutical  Product  Development  
[ADDRESS_662280]  version.  I understand it,  and I will work  
according to the  principles  of Good  Clinical Practice  (GCP)  as described in the  [LOCATION_002]  Code  of 
Federal  Regulations  (CFR)  – 45 CFR part 46 and 21 CFR parts  50, 56, and 312,  and in the International  
Conference  on Harmonization (ICH)  document Guidance  for Industry: E6 Good Clinical Practice:  
Consolidated Guidance  dated April  1996.  Further,  I will conduct  the study  in keepi[INVESTIGATOR_512018].  
As the site Principal Investigator,  I agree  to carry out the study  by [CONTACT_512044].  
 
Site Principal  Investigator   (Print) 
 
Site Principal  Investigator  (Signature)  Date 
 
 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  3 of 37  
  
Protocol Synopsis  
 
Title A Biomarker- Based  Pi[INVESTIGATOR_512019]  (SCITMO) 
Clinical  Phase I/IIa 
Number  of Sites Multiple 
Study  Objectives  The primary objective  of the study is  to assess  if treatment with  
mouse  SCIT,  using the  per protocol  allergenic  extract doses, is safe.  
This will be done  by [CONTACT_512045].  
Secondary objectives  are: 
1. To determine  whether  a [ADDRESS_662281]  administered  
by [CONTACT_512046] 10 adults  ages  18 to 55 years  with  
asthma  and mouse  sensitivity.  It is designed  to study the  safety of 
this therapy as  well as biomarkers  of the immune  response. 
Primary Endpoint(s)  The number  of reported  adverse  events  and serious  adverse  
events,  including their  severity,  seriousness,  and treatment 
relatedness.  
Secondary Endpoint(s)  1. Changes  in levels  of mouse  specific  IgE observed after  
initiation  of study  treatment.  
2. Changes  in mouse specific  IgG and IgG4.  
3. Change  in in -vitro mouse  antigen binding to B-cells 
Accrual  Objective Approximately  [ADDRESS_662282]  
by [CONTACT_512047] 0.4 ml of 
1:20 wt/vol.  
Inclusion Criteria  1. Male  or female  adults,  [ADDRESS_662283]  100 mcg  
fluticasone  per day or the equivalent  of another  
inhaled corticosteroid.  
c. The participant’s  asthma  must  be well controlled  
as defined by:  
i. A FEV1  greater than or  equal  to 70% 
predicted  with  or without  controller 
medication (see  Section  8.2). 
ii. An Asthma  Control  Test  (ACT)  score  ≥ 20. 
3. Are sensitive  to mouse  as documented by a positive  (≥ 3 
mm greater than negative  control)  skin prick  test result  
(using the  same  extract  used  for immunotherapy)  and 
detectable  mouse  specific  IgE (≥0.10 kUA/L).  
4. Have  no known  contraindications  to therapy with  
glycerinated mouse  allergenic  extract  or placebo.  
5. Are willing to  sign the written Informed Consent  prior to 
initiation  of any study procedure.  
Exclusion  Criteria 1. Are pregnant  or lactating.  Females  must  be abstinent  or 
use a medically  acceptable  birth control method  
throughout  the study  (e.g.  oral,  subcutaneous,  mechanical,  
or surgical contraception).  
2. Cannot  perform  spi[INVESTIGATOR_512020].  
3. Have  an asthma  severity classification at  Screening  of 
severe  persistent, using the NAEPP  classification,  as 
evidenced by  [CONTACT_469151]:  
a. Require  a dose  of greater than [ADDRESS_662284]  access  to a phone  (needed for  scheduling  
appointments).  
5. Have  received allergen immunotherapy (SLIT  or SCIT)  in 
the last [ADDRESS_662285]  received an  investigational drug in the  30 days  prior  
to Screening  or who  plan to  use an investigational  drug  
during the  study.  
8. Refuse  to sign the  Epi[INVESTIGATOR_512021] -injector  Training  
Form.  
Participants  who  meet  any of the following  criteria  are not eligible  
for enrollment  and may  not be reassessed.  Participants  are 
ineligible  if they:  
9. Do not primarily  speak  English.  
10. Plan to move  from the  area during the  study period.  
11. Have  a history within the past 5 years of idiopathic  
anaphylaxis  or anaphylaxis  grade  2 or higher  as 
defined in section  [IP_ADDRESS],  Grading  Criteria  for 
Anaphylaxis.  
12. Have  unstable  angina,  significant  arrhythmia,  uncontrolled  
hypertension,  history  of autoimmune  disease,  or other  
chronic  or immunological  diseases  that in the opi[INVESTIGATOR_512022].  
13. Are using tricyclic  antidepressants  or beta -adrenergic  
blocker  drugs  (both oral  and topi[INVESTIGATOR_2855]).  
14. Have  not received and refuse  to receive  the Flu Vaccine  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  6 of 37  
 Study  Stoppi[INVESTIGATOR_512023]: 
1) 1 death  regardless  of relationship to the investigational  agent  
2) 1 anaphylactic  reaction grade  3 possibly related to  the 
investigational agent  
3) Either of the following events, if considered related to the study 
procedures or treatments, in at least 2 participants : 
a) Anaphylactic  reaction grade  2. 
b)  Hypotensive  shock:  Drop  in blood  pressure:  Systolic  < 90 
mm Hg or  < 80%  of baseline,  whichever  is higher,  and 
diastolic  blood pressure  < [ADDRESS_662286]  or Intervention  ....................................................................... 13 
1.3 Precl inical Experience ............................................................................................................................................ 13 
1.4 Clinical  Studies  ...................................................................................................................................................... 13 
2 Study  Hypotheses/Objectives  ....................................................................................................................................... 13 
2.1 Hypotheses  ........................................................................................................................................................... 13 
2.2 Primary Objectives  ................................................................................................................................................ 13 
2.3 Secondary Objective(s).......................................................................................................................................... 14 
3 Study  Design.................................................................................................................................................................. 14 
3.1 Description  of Study  Design ......................................................................................................................................... 14 
3.2 Primary Endpoints  ................................................................................................................................................. 14 
3.3 Secondary Endpoints  ............................................................................................................................................. 14 
4 Selection  of Participants  and Clinical  Sites/Laboratories  .............................................................................................. 15 
4.1 Rationale  for Study Population ............................................................................................................................. 15 
4.2 Par
ticipant  Inclusion Criteria ........................................................................................................................................ 15 
4.3 Participa nt Exclusion Criteria ....................................................................................................................................... 15 
5 Known  and Potential  Risks and Benefits  to Participants  ............................................................................................... 16 
5.1 Risks  of Study Procedures  ..................................................................................................................................... 16 
5.2 Potential  Benefits  .................................................................................................................................................. 17 
6 Investigational  Agent  .................................................................................................................................................... 17 
6.1 Investigational  Agent  ............................................................................................................................................ 17 
6.1.1 Formulation,  Packaging,  and Labeling  ........................................................................................................... 17 
6.1.2 Dosage,  Preparation,  and Administration  ..................................................................................................... 17 
6.2 Drug Accountability  ............................................................................................................................................... 17 
6.3 Assessment  of Participant  Compliance  with Investigational  Agent  ...................................................................... 18 
6.4 Toxicity Prevention  and Management  .................................................................................................................. 18 
6.5 Premature  Discontinuation  of Investigational  Agent  ................................................................................................. 18 
7 Other  Medications  ........................................................................................................................................................ 18 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  8 of 37  
 7.1 Concomitant  Medications  ..................................................................................................................................... 18 
7.1.1 Protocol -mandated  ....................................................................................................................................... 18 
7.1.2 Other  permitted concomitant  medications  .................................................................................................. 18 
7.2 Prophylactic  Medications  ...................................................................................................................................... 19 
7.3 Prohibited Medications  ......................................................................................................................................... 19 
7.4 Rescue  Medications  .............................................................................................................................................. 19 
8 Study  Procedures  .......................................................................................................................................................... 19 
8.1 Recruitment  .......................................................................................................................................................... 19 
8.2 Screening/Baseline  Visit  ........................................................................................................................................ 19 
8.3 Asthma  Control Optional  Visits  ............................................................................................................................. 20 
8.4 Dose  Initiation ....................................................................................................................................................... 20 
8.5 Follow -up .............................................................................................................................................................. 21 
8.5.1 Dose  Escalation  ............................................................................................................................................. 21 
8.5.2 Maintenance  Visits  ........................................................................................................................................ 22 
8.6 Final  Study  Visit  ..................................................................................................................................................... 22 
8.7 Early  Termination  Visit  .......................................................................................................................................... 23 
8.8 Pregnancy Visit  ...................................................................................................................................................... 23 
8.9 Unscheduled Visits  ................................................................................................................................................ 23 
8.10 Vis
it Windows  ....................................................................................................................................................... 23 
9 Mechanistic  Assays  ....................................................................................................................................................... 23 
10 Biospecimen  Storage  ................................................................................................................................................. 23 
11 Criteria  for Participa nt and Study  Completion and  Premature  Study Termination  ................................................... 23 
11.1 Participant  Completion  ......................................................................................................................................... 24 
11.2 Participant  Stoppi[INVESTIGATOR_106442]  ............................................................................................. 24 
11.3 Participant  Replacement  ....................................................................................................................................... 24 
11.4 Follow -up after  Early Study Withdrawal ............................................................................................................... 24 
11.5 Study  Stoppi[INVESTIGATOR_1869]  ............................................................................................................................................. 24 
12 Safety Monitoring and Reporting  .............................................................................................................................. 25 
12.1 Overview  ............................................................................................................................................................... 25 
12.2 Definitions  ............................................................................................................................................................. 25 
12.2.1  Adverse  Event  (AE) ........................................................................................................................................ 25 
12.2.2  Suspected Adverse  Reaction (SAR) ............................................................................................................... 26 
12.2.3  Unexpected Adverse  Event  ........................................................................................................................... 26 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  9 of 37  
 12.2.4  Serious  Adverse  Event  (SAE) .......................................................................................................................... 26 
12.3 Grading and Attribution  of Adverse  Events  ........................................................................................................... 27 
12.3.1  Grading Criteria  ............................................................................................................................................. 27 
12.3.2  Grading Criteria for Anaphylaxis  ................................................................................................................... 27 
12.3.3  Attribution  Definitions  .................................................................................................................................. 28 
12.4 Collection and  Recording of  Adverse  Events  ......................................................................................................... 28 
12.4.1  Collecting Adverse  Events  ............................................................................................................................. 28 
12.4.2  Recording Adverse  Events  ............................................................................................................................. 29 
12.5 Reporting  of Serious  Adverse  Events  and Adverse  Events  .................................................................................... 29 
12.5.1  Reporting  of Serious  Adverse  Events  to Sponsor  (DAIT/NIAID)  .................................................................... 29 
12.5.2  Reporting  to Health Authority  ....................................................................................................................... 29 
12.5.3  Reporting  of Adverse  Events  to IRBs ............................................................................................................. 30 
12.6 Pregnancy Reporting ............................................................................................................................................. 30 
12.7 Reporting  of Other  Safety  Information  ................................................................................................................. 31 
12.8 Review  of Safety Information ................................................................................................................................ 31 
12.8.1  Medical Monitor  Review  ............................................................................................................................... 31 
12.8.2  DSMB  Review  ................................................................................................................................................  31 
13 Sta
tistical  Considerations  and Analytical  Plan  ........................................................................................................... 32 
13.1 Overview  ............................................................................................................................................................... 32 
13.2 Endpoints  .............................................................................................................................................................. 32 
13.2.1  Primary Endpoints  ......................................................................................................................................... 32 
13.2.2  Secondary Endpoints  ..................................................................................................................................... 32 
13.3 Measures  to Minimize  Bias ................................................................................................................................... 32 
13.4 Analysis  Plan  .......................................................................................................................................................... 32 
13.4.1  Analysis  Population  ....................................................................................................................................... 32 
13.4.2  Primary  Analysis  of Primary Endpoint(s)/Outcome(s) ................................................................................... 32 
13.4.3  Analyses  of Secondary  Endpoints  ................................................................................................................. 32 
13.4.4  Analyses  of Exploratory  Endpoint(s)/Outcome(s)  ......................................................................................... 33 
13.4.5  Descriptive  Analyses ...................................................................................................................................... 33 
13.5 Interim  Analyses  .................................................................................................................................................... 33 
13.6 Sample  Size Considerations ................................................................................................................................... 33 
14 Identification  and Access  to Source  Data .................................................................................................................. 33 
14.1 Source  Data ........................................................................................................................................................... 34 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  10 of 37  
 14.2 Access  to Source  Data  ........................................................................................................................................... 34 
15 Protocol  Deviations  ................................................................................................................................................... 34 
15.1 Protocol  Deviation  Definitions  .............................................................................................................................. 34 
15.1.1  Protocol  Deviation  ......................................................................................................................................... 34 
15.1.2  Major  Protocol  Deviation (Protocol Violation)  .............................................................................................. 34 
15.1.3  Non-Major Protocol  Deviation  ...................................................................................................................... 34 
15.2 Reporting and  Managing Protocol  Deviations  ....................................................................................................... 34 
16 Ethical  Considerations  and Compliance  with Good Clinical  Practice  ......................................................................... 35 
16.1 Statement  of Compliance  ...................................................................................................................................... 35 
16.2 Informed Consent  Process  .................................................................................................................................... 35 
16.3 Privacy  and Confidentiality .................................................................................................................................... 35 
17 Publication  Policy  ...................................................................................................................................................... 35 
18 References  ................................................................................................................................................................ 35 
Appendix  A:   Schedule  of Procedures/Evaluations  .......................................................................................................... 37 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  11 of 37  
 Glossary  of Abbreviations  
 
 
AE Adverse  Event/Adverse  Experience  
CFR Code  of Federal  Regulations  
CRF Case  Report  Form 
CTCAE Common Terminology  Criteria  for Adverse  Events 
DAIT Division  of Allergy,  Immunology,  and Transplantation  
DSMB Data  Safety  Monitoring Board 
FDA Food  and Drug Administration  
GCP Good  Clinical  Practice 
HIPAA Health Insurance  Portability  and Accountability Act  
ICH International  Conference  on Harmonization  
IND Investigational  New  Drug 
IRB Institutional  Review  Board 
MOP Manual  of Procedures  
MSD Maximum Study Dose  
NAEPP The National  Asthma  Education and  Prevention  Program 
NIAID National  Institute  of Allergy  and Infectious  Diseases 
NIH National  Institutes  of Health 
OHRP Office  for Human Research  Protections  
PHI Protected Health Information  
PI [INVESTIGATOR_512024]  2.[ADDRESS_662287]  allergen also plays  an important  role in asthma  morbidit y.1-4 Like Bla g 1, the major        
mouse  allergen,  Mus  m 1, is detectable  in a very high proportion  of inner -city homes  and is  present  in 100- fold higher  
concentrations in inner -city homes  compared to  suburban homes .5,6 Mouse  allergen  exposure  is also a well-recognized  
risk factor  for occupational  asthma,  with  30-50%  of laboratory mouse  workers  experiencing  mouse -related  allergic  
symptoms,  and 20%  with skin test  sensitivity  to mouse.[ADDRESS_662288] sensitization rates  of 17-50% .2,8-[ADDRESS_662289] that 
both  the prevalence  of mouse  sensitization and  the intensity of Mus  m 1 exposure  in the  inner -city are similar  to that 
observed in  occupational  settings  – where  mouse  allergen  is a known cause  of asthma  symptoms – provides  a 
compelling rationale  for a causal link between mouse  allergen exposure  and asthma  in the  inner -city. 
 
As with cockroach allergen,  the only currently available  treatment for mouse  allergy  is avoidance  and eradication. 
Studies  aimed at  the eradication  of mice  in home  environments  have  had some  success;  however,  the fact remains  
that multifaceted  environmental  eradication programs  are extremely  difficult  to implement  in inner  city environments  
with limited resources.   As such,  a more  definitive  treatment  may  be desensitization of patients  with  mouse  allergy  
using allergen immunotherapy.  
Given  these  data,  a major ICAC  goal is to conduct  a large  multi -center  efficacy trial  of immunotherapy,  including   
mouse  allergen,  in inner -city asthma.  While  we have  pursued the  possibility of using sublingual  immunotherapy  (SLIT)  
given its  excellent  safety  profile,  data  from the  BioCSI  and BioCSI2 studies  (ICAC -12 and ICAC -17) of cockroach SLIT   
have  raised the  possibility that  SLIT for cockroach  may  not be effective  due to limitations  in the  maximum  doses  that 
can be  provided with currently  available  extracts.  These  studies  have  also generated concerns  about  the likelihood  of 
compliance  with daily  SLIT therapy,  an issue  that may  both  reduce  efficacy and potentially  increase  risk. Given those  
concerns,  a pi[INVESTIGATOR_512025] 10  adults  (SCITCO,  ICAC -18) with a primary  focus  on 
safety in an effort  to lay the groundwork  for an efficacy  study  using SCIT.  The SCITCO  study  demonstrated an  excellent  
safety profile,  as well as robust  biomarkers  of immunologic  response.  Given that  mouse  allergen is also a key inner - 
city allergen,  and that there  is a paucity of experience  with  mouse  immunotherapy,  the current  study  is designed to 
provide  similar  safety and immunologic  data  for mouse  that SCITCO  provided for  cockroach.  
While  studies  of c ockroach  and mouse  are limited,  there  is a vast clinical  and research experience  with  the use of SCIT  
for the treatment  of asthma  and allergic rhinitis,  as well as stinging insect  hypersensitivit y.11,[ADDRESS_662290]  or Intervention 
The study agent  for this protocol  is 1:20 w/v  glycerinated  mouse  epi[INVESTIGATOR_512026]  (Lenoir,  NC).  Mouse  Epi[INVESTIGATOR_24603]  (Mus  musculus)  allergic  extract  
is approved in the  United  States  for diagnostic  skin testing and immunotherapy  by [CONTACT_63275] (US License  
NO. 308).  While  mouse  SCIT has undergone  little  prior  study  and specific  dosing guidelines  have  not been established,  
there is a large  body of literature  for other  allergens  that can be  applied to  choose  a dose  schedule  for this protocol  
that should  maximize  safety  and efficacy. For other  allergens,  maintenance  doses  of major  allergens  ranging from  [ADDRESS_662291]  proven  effective  and our dosing  strategy  will seek  to achieve  a maintenance  dose  within  this 
range,  with  a secondary  goal of minimizing injection volume  so that this same  dose  could eventually be  applied to a 
multi -allergen  protocol  in pediatric  patients. 
1.3 Preclinical Experience 
Not applicable.  
 
1.4 Clinical  Studies  
Only  one study of mouse  immunotherapy  has previously  been published .14   That  study  was conducted in  23 laboratory  
animal workers,  11 of whom  received immunotherapy  with 12  different  extracts  (five  mouse,  six rat, one rabbit),  and 
12 were  matched untreated  controls.  The maximum  weekly  immunotherapy  dose  for the different  allergens  ranged  
from 2,000 to 10,000 protein nitrogen units  (PNU).  Among  the treated patients,  nine  of 11 subjectively  improved with  
immunotherapy  and blocking antibody titers  were  significantly  elevated in  the treated subjects  compared to the 
controls  (specific  data on mouse  were  not provided).  There  were  no systemic  reactions  reported,  nor any need to  
discontinue  dosing due  to adverse  reactions. 
It is important  to re cognize,  however,  that even  though there  are a minimal data  regarding mouse, there  is a vast body  
of literature  and cli nical  experience  with the use of SCIT for other  allergens. A recent  practice  parameter detailed the  
use of SCIT  for inhalant  allergens  as well as stinging ins ects.[ADDRESS_662292]  been necessary  to treat  4 patients  with immunotherapy  to avoid 1 deterioration in asthma  
symptoms  and 5 patients  to avoid  1 requiring increased asthma  medication. 
 
 
2 Study  Hypotheses/Objectives  
2.1 Hypotheses  
The two hypotheses  tested  by [CONTACT_307702] 1) Subcutaneous  treatment with mouse  extract  can be  safely  
administered in adults  with  mouse  sensitivity and 2) Subcutaneous  treatment  with  mouse  extract can induce  
significant  changes  in serum  biomarkers  indicative  of immunologic  activity. 
2.[ADDRESS_662293]  doses,  is safe.  This will be done  by [CONTACT_512048].  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  14 of 37  
  
2.3 Secondary  Objective(s)  
1. To determine  wheth er a [ADDRESS_662294]  for a period of approximately 24 weeks.  It is primarily  designed  to study  the 
safety of this therapy.  
 
Mouse  IT 
 
 
Screening Escalation  Maintenance  
| | | | | | | | | | | | | 
Week 1-[ADDRESS_662295]  will need to  reach  the maintenance  
dose  in a maximum of 18 weeks.  Once  the maintenance  dose  is achieved,  bi-weekly visits  will continue  to complete  a 
total  of 24 weeks  of treatment.  
Blood  will be collected at  baseline  and then monthly  for assessment  of biomarkers  of allergen immunotherapy,  
including mouse  specific  IgE, IgG, IgG4,  and inhibition of mouse  antigen  binding to B-cells.  Mouse  skin testing will be 
performed at  screening.  (See  Visit  Activities  Summary,  Appendix  A) 
Adverse  events  (AEs) will be assessed at each study visit.  Allergy and asthma symptom  questionnaires  will also be 
administered throughout  the study.  
3.2 Primary Endpoints  
The primary endpoint  is the number  of reported adverse  events  and serious  adverse events,  including their  severity,  
seriousness, and treatment  relatedness.  
3.3 Secondary  Endpo ints 
1. Change  in mouse specific  IgE. 
2. Change  in mouse specific  IgG and IgG4. 
3. Change  in in -vitro mouse  antigen binding to B-cells  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  15 of 37  
  
4 Selection  of Participants  and Clinical  Sites/Laboratories  
4.[ADDRESS_662296]  an immunotherapy  
efficacy trial  that will include  mouse  allergen.   Given  that there  has been so little  study of mouse  immunotherapy,  
adults  will be studied in this  safety  trial. 
4.2 Participant  Inclusion  Criteria  
Participants  who  meet  all of the following  criteria  are eligible  for enrollment. Participants  may  be reassessed  if not 
initially  eligible.  Participants  are eligible  if they:  
 
1. Are male  or female  adults,  [ADDRESS_662297]  100 mcg of 
fluticasone  per day or the equivalent  of another  inhaled corticosteroid.  
iii. The participant’s  asthma  must  be well controlled as  defined by:  
1. A FEV 1 greater  than or equal  to 70% predicted  with  or without  controller  medication. (see  
Section  8.2).  
2. An Asthma  Co ntrol  Test  (ACT)  score  ≥ 20. 
 
3. Are sensitive  to mouse  as documented by a positive  (≥ 3 mm greater than negative  control)  skin prick  test 
result  (using the  same  extract  used for  immunotherapy)  and detectable mouse  specific  IgE (≥ 0.10 kU A/L). 
 
4. Have  no known  contraindications  to therapy with  glycerinated  mouse  allergenic  extract.  
 
5. Are willing to  sign the written Informed Consent  prior to initiation  of any study  procedure.  
 
 
4.3 Participant  Exclusion Criteria  
Participants  who  meet  any of the following  criteria  are not eligible  for enrollment  but may  be reassessed.  Participants  
are ineligible  if they:  
1. Are pregnant  or lactating.  Females  must  be abstinent  or use a medically  acceptable  birth control method  
throughout  the study  (e.g.  oral,  subcutaneous,  mechanical,  or surgical  contraception).  
2. Cannot  perform  spi[INVESTIGATOR_512020].  
3. Have  an asthma  severity classification at  Screening  of severe  persistent, using the NAEPP  classification,  as 
evidenced by  [CONTACT_469151]:  
a. Require  a dose  of greater than [ADDRESS_662298]  access  to a phone  (needed for scheduling appointments).  
5. Have  received allergen immunotherapy (SLIT  or SCIT)  in the  last [ADDRESS_662299]  received an  investigational drug in the  30 days  prior  to Screening  or who  plan  to use an investigational  
drug during the  study.  
8. Refuse  to sign the  Epi[INVESTIGATOR_512021] -injector  Training  Form.  
 
 
Participants  who  meet  any of the following  criteria  are not eligible  for enrollment  and may  not be reassessed.  
Participants  are ineligible  if they:  
1. Do not primarily  speak  English.  
2. Plan to move  from the  area during the  study period.  
3. Have  a history of idiopathic  anaphylaxis  within the past [ADDRESS_662300]  unstable  angina,  significant  arrhythmia,  uncontrolled hypertension,  history of autoimmune  disease, or 
other  chronic  or immunologic al diseases  that in the  opi[INVESTIGATOR_512027]. 
5. Are using tricyclic  antidepressants  or beta -adrenergic  blocker  drugs  (both oral  and topi[INVESTIGATOR_2855]).  
6. Have  not re ceived and refuse  to receive  the Flu Vaccine.  
 
 
5 Known  and Potential  Risks  and Benefits  to Participants  
5.1 Risks  of Study Procedures  
Risks  of exposing participants  to allergens  via immunotherapy  include,  but are not limited to:  itching of the mouth,  
ears,  and throat,  itching  or swelling of  the eyes,  nasal congestion,  sneezing,  rhinorrhea,  oral or throat  angioedema,  
cough,  chest  tightness,  wheezing,  gastrointestinal  symptoms  (vomiting,  diarrhea,  abdominal  pain),  skin symptoms  
(rash,  hives,  swelling,  itching),  and anaphylaxis.  We expect  that the main  sign/symptom experienced by [CONTACT_512049]  30 minutes  after administration  of the immunotherapy  
injection.  Large  local  reactions  associated w ith allergen  immunotherapy  are common,  with  a frequency  ranging from  
26%  to 86%  of injection s.[ADDRESS_662301]  been reported to 
occur  in from  1% of patients  to as many as  36%  of patients  receiving  SCIT  using a rush schedul e.20,[ADDRESS_662302]  specific  risk 
factors  for fatal  reactions,  which include  unstable  asthma,  beta -blocker  therapy,  rush immunotherapy,  and use of high  
doses  of potent  standardized extracts .20 In our SCITCO  study,  in 10  adults  undergoing six  months  of SCIT,  there  were  2 
serious  adverse  events  reported,  neither  of which  were  considered  related  to the therapy .22 
The risks  to a fetus  are unknown  and SCIT  is generally  not initiated during pregnancy.  Pregnant  females  will be 
excluded from  the present protocol.  Urine  pregnancy testing will be performed at  the Screening Visit  and monthly  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  17 of 37  
  
thereafter  to ensure  no pregnant  female will  be entered into the study  and any  female  becoming pregna nt during the  
course  of the study will  be discontinued.  
5.2 Potential Benefits  
There are no known potential  benefits  for the participant  in this  trial.  The participant’s  allergic  rhinitis  or asthma  may  
or may  not improve  while  in this study.  In the longer  term,  this study may  promote  the further  development  of mouse  
SCIT  for asthma  and allergic  rhinitis,  which  could be  a major  advance  in the care  of individuals  with these  conditions  
who  are allergic  to mouse  antigens. 
 
 
[ADDRESS_662303]  or placebo  administered via the 
subcutaneous  route  up to a Maximum  Study Dose  (MSD)  of 0.[ADDRESS_662304]  at a concentration of 1:20 wt/vol.  
 
6.1.[ADDRESS_662305]  (50%  Glycerin).  The active  ingredient of the 
investigational  agent  is a non-standardized allergen derived  from the  extraction  and purification  of proteins  from  
mouse  epi[INVESTIGATOR_24603]  (mouse  epi[INVESTIGATOR_512028] ). 
The investigational agent will be manufactured Greer  laboratories,  Lenoir  NC. Glycerinated  Mouse  Epi[INVESTIGATOR_24603]  (Mus  
musculus)  allergic  extract is approved in the  [LOCATION_002]  for diagnostic  skin testing and immunotherapy  by 
[CONTACT_63275] (US  License  NO. 308).   It has been used in humans  for at least  [ADDRESS_662306]  needed  for dose  escalation  will be prepared by  a research pharmacy.  
Complete  details  can be  found in the  Manual  of Operations  (MOP),  which is  based on the DAIT  Pharmacy  manual  and 
AAAAI practice  parameters. 
Participants  will receive  escalating doses  of glycerinated  mouse  allergenic  extract  administered via the subcutaneous  
route  up to a MSD of 0.[ADDRESS_662307]  at a concentration of 1:20 wt/vol.  See Section 8.45 for the dose  escalation  
schedule.  
The investigational agent  will be shipped by [CONTACT_512050].  On site the 
investigational  agent  will be stored at  -2° C. 
6.2 Drug Accountability  
Under  Title  21 of the Code  of Federal  Regulations  (21CFR  §312.62)  the investigator  will maintain adequate  records  of 
the disposition  of the investigational  agent,  including the  date  and quantity of the drug received,  to whom the  drug  
was dispensed (participant -by-participant  accounting),  and a detailed accounting  of any drug accidentally  or 
deliberately  destroyed.  
Records  for receipt,  storage,  use, and disposition  will be maintained by [CONTACT_512051].  A drug -dispensing log will be 
kept  current  for each participant.  This log will  contain the  identification  of each  participant  and the  date  and quantity  
of drug dispensed.  
 
All records  regarding the  disposition of the investigational product  will be available  for inspection.  
Version  2.[ADDRESS_662308]  been met and approval  has 
been received from DAIT/NIAID. 
6.3 Assessment  of Participant  Compliance with  Investigational  Agent  
As participants  will receive  their  injections  in the clinic,  compliance  will be monitored by  [CONTACT_512052]. 
6.4 Toxicity  Prevention and Management  
In the  case  of a reaction to the  study medication,  dosing  will be altered in  the following  manner:  
 
• For local  reactions  6-11 cm in diameter,  the dose  will be repeated.  
 
• For local  reactions  greater  than 12 cm, the dose  will be reduced  to the prior  dose  during escalation and cut  by 
50%  while  on maintenance  with re -escalation  the following week.  
 
• For mild systemic  symptoms  (Grade  1 anaphylaxis),  the dose  will be reduced by 2 doses  during escalation  or 
reduced cut  by 75%  while  on maintenance  with  re-escalation  over  the next  [ADDRESS_662309] 8 injections  following the  Dose  Initiation Visit  will be unable  to 
proceed to  the maintenance  period and may  be replaced (see  Section  11.2,  Participant  Stoppi[INVESTIGATOR_512029] ). Subjects  unable  to continue  beyond that  point  will not be replaced.   A final blood  sample  will be drawn on 
participants  who  need to  discontinue  therapy.  
 
Study  therapy may  be prematurely  discontinued for  any participant  for any of the following reasons:  
 
1. SAE related to  investigational agent  
2. Anaphylactic  reaction grade  2 or 3 (see Section 12.3.2,  Grading Criteria  for Anaphylaxis ) 
3. Inability  to tolerate the  build up to or the MSD  due to excessive  discomfort/symptoms  or large  local  reactions  
after  a second attempt  at dose  escalation  
4. Development  of any serious  medical  illness  whose  natural history,  sequela,  or treatment would be  worsened  
or impaired by [CONTACT_512053]  
5. The study treatment is no longer  in the best  interest of the participant  
6. Pregnancy  
 
 
7 Other  Medications  
7.1 Concomitant  Medications  
 
7.1.1 Protocol -mandated  
Not applicable.  
 
7.1.2 Other  permitted concomitant  medications  
During the  study,  after  the initial  skin testing,  rhinitis  and asthma  medications  will be permitted along with other  
maintenance  medications,  aside  from those  excluded  in Section  4.3, Participant  Exclusion Criteria. A dose  of greater  
than 500 mcg  of fluticasone  per day or the equivalent  of another  inhaled corticosteroid may  be used short -term to  
control  an asthma  exacerbatio n. 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  19 of 37  
  
7.2 Prophylactic  Medications  
Not applicable.  
7.3 Prohibited Medications  
1. A regular dose  of greater  than 500 mcg  of fluticasone  per day or the equivalent  of another  inhaled  
corticosteroid.  
2. Allergen immunotherapy (SLIT  or SCIT)  
3. Anti-IgE therapy  
4. Tricyclic  antidepressants  
5. Beta -adrenergic  blocker  drugs  (both oral and topi[INVESTIGATOR_2855])  
6. Any investigational  drug  
 
Antihistamines  will need to be  suspended prior  to skin testing at the screening and  final  visits. 
 
7.[ADDRESS_662310]  sign the  epi[INVESTIGATOR_130508] -injector  
training form  and understand its  use before  they  can be enrolled in the  study and receive the  investigational agent.  
 
 
8 Study  Procedures  
8.1 Recruitment  
The study center  may  use any IRB-approved  means  to identify  potential  participants.  Examples  include  hospi[INVESTIGATOR_307],  clinic,  
or emergency department  admission records; investigators’  specialty clinic  records;  and advertising (in public  locations  
and on the radio). Potential  participants  will be screened and recruited using a standardized questionnaire  that   
collects  contact  [CONTACT_106495]/exclusion criteria information. Participants  may  be recruited by [CONTACT_512054].  
Retention  methods  involve  a number  of different  approaches.  Appointment  reminder  cards  are given at  each visit.  
We will use an appointment  reminder  system that  consists of phone  calls  and/or  text messages several  days  and one  
day prior  to scheduled appointments  for confirmation.  To facilitate  telephone  contact  [CONTACT_512055],  at least  three telephone  contact  [CONTACT_15750]  (relatives,  neighbors,  friends)  will be 
collected for  each subject.  This has proven  to be an effective  strategy  in previous  ICAC  studies.  Those  who  have  no 
obvious  characteristics  making them  ineligible  and who  are interested  will be invited  to the clinic  for a Screening Visit.  
8.2 Screening/Baseline Visit  
Th
is research study  will be explained in lay terms  to each potential  research participant. The potential  participant  will 
provide  informed  consent  before  he or she undergoes  any screening study  procedures.  Written informed consent  and 
Health Insurance  Portability  and Accountability Act  (HIPAA)  authorization  will be obtained from  all participants  at the 
beginning of this  visit.  Study  procedures  will be stopped and the  participant  will be deemed ineligible  for the study at  
any point  during the  Screening Visit  if and when  they  fail to meet  eligibility criteria.  
After  the consent  is signed,  participants  will undergo screening study procedures,  including prick  skin tests  with mouse  
allergenic  extract  to ensure  participants  are sensitive  to the test product,  since  those  who do  not react  to mouse  are 
excluded from  the remainder of the study.  In addition,  participants  will be tested  with:  American cockroach,  German  
Version  2.[ADDRESS_662311]  mite,  and selected seasonal  aeroallergen  allergenic  extracts,  as specified in 
the study MOP,  to characterize  the study  population.  
A medical  history will  be taken and a targeted  physical  examination will  be performed  to verify  the participant’s  
suitability  for inclusion in the  study.  A urine  pregnancy  test will also be performed  on all female  participants. 
Spi[INVESTIGATOR_512030]’s  suitability  for inclusion in the  study.  
Candidates  whose  FEV1 is  less than  70% of predicted  normal  will be excluded;  however,  if their  asthma  can be brought  
under  control  within [ADDRESS_662312]  and a mouse -specific  IgE ≥ 0.10 kU A/L 
and are  considered  eligible  for the study,  and at  the discretion of  the study clinician,  will be invited to proceed to the 
Dose  Initiation Visit. 
 
8.3 Asthma  Control  Optional  Visits  
Participants  who s e FEV1  is less than  70% of predicted  normal  or whose  asthma  is not well controlled  as defined by  [CONTACT_512056]. 
8.[ADDRESS_662313] injection  will contain 0.05 mL  of 1:10,000 concentration of  1:20 w/v  glycerinated  mouse  allergenic  extract  as 
detailed in the  Dose  Escalation  Table  8.5.1. Each injection will  be administered by  [CONTACT_512057],  as required.  Refer  to the MOP  for information on handling treatment -related reactions.  Prior to 
the administration of  each  dose  of allergenic  extract,  the study clinician  will assess  the eligibility of the participant  to 
receive  the allergenic  extract  injection and  will review any  side-effects  or adverse  reactions  experienced by [CONTACT_162348]. Participants  will report  symptoms,  using a questionnaire,  [ADDRESS_662314]  information gathered and assessed on any delayed reactions  or side 
effects  experienced,  regardless  of whether  or not they continue  on to the 24 week  treatment course.  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  21 of 37  
  
8.5 Follow -up 
 
8.5.1 Dose Escalation 
Dose  escalation will  be conducted by [CONTACT_512058]:  
 
Table 8.5.1 Dose Escalation  
 
Dose  # Week*  # Concentration  Volume Approximate  Dose Mus m 1 
1 1 1:10,000 0.05 ml   
2 1 1:10,000 0.10 ml   
3 2 1:10,000 0.20 ml   
4 2 1:10,000 0.40 ml   
5 3 1:1,000 0.05 ml   
6 3 1:1,000 0.10 ml   
7 4 1:1,000 0.20 ml   
8 4 1:1,000 0.40 ml   
9 5 1:100 0.05 ml   
10 5 1:100 0.10 ml   
11 6 1:100 0.20 ml   
12 6 1:100 0.40 ml   
13 7 1:10 0.05 ml   
14 7 1:10 0.10 ml   
15 8 1:10 0.20 ml   
16 8 1:10 0.40 ml   
17 9 1:1 0.05 ml   
18 9 1:1 0.10 ml   
19 10 1:1 0.15 ml   
20 10 1:1 0.20 ml   
21 11** 1:1 0.30 ml   
22 11 1:1 0.40 ml   
Maint.*** 12-24 1:1 0.40 ml  6.2 mcg 
* During dose  escalation,  [ADDRESS_662315]  2 days  
** Dose  escalation  may  be accomplished  over  a maximum of 18 weeks  
*** During maintenance,  doses  will be given every  [ADDRESS_662316]  will need  
to reach the maximum study  dose  in a maximum of 18 weeks.  A clinician  and appropriate  emergency  supplies  will be 
readily  available  to treat  any adverse  reactions. Participants  will be discharged after  the 30 minute  waiting period if  
they  show  no signs  or symptoms  greater  than mild,  as defined in Section 12.3.1,  or at the discretion  of the study  
clinician. 
Dose  escalation will  continue  according to the schedule  unless  there  are lapses  in dosing or reactions  occur.   Dosing  
will be modified as  follows  for lapses  in dosing or reactions:  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  22 of 37  
  
• For a lapse  in dosing of more  than two weeks  during escalation,  the dose  from the previous  visit will be 
repeated.  
• For a lapse  in dosing of more  than three  weeks  during  escalation,  the subject will be discontinued from the  
protocol.  
 
• For one missed dosing visit while  on maintenance,  the maintenance  dose  will be continued. 
 
• For two missed  maintenance  doses  while  on maintenance,  the dose  will be reduced by 50%  and re -escalated  
the following week.  
• For more  than  two consecutive  missed dosing visits  while  on maintenance,  the subject  will be discontinued  
from the  protocol.  
 
• For local  reactions  6-11 cm in diameter,  the dose  will be repeated.  
 
• For local  reactions  greater  than 12 cm, the dose  will be reduced  to the prior  dose  during escalation and cut  by 
50%  while  on maintenance  with re -escalation  the following week.  
• For mild systemic  symptoms  (Grade  1 anaphylaxis),  the dose  will be reduced by 2 doses  during escalation  or 
reduced cut  by 75%  while  on maintenance  with  re-escalation  over  the next  2 weeks.  
 
Participants  who  are unable  to reach the  Maximum  Study  Dose  by 18 weeks  following  the Dose  Initiation Visit  will be 
unable  to proceed to the  maintenance  period and  may be  replaced (see  Section 11.2,  Participant  Stoppi[INVESTIGATOR_512031]). 
 
8.5.[ADDRESS_662317] clinical  practice  
as described in  the MOP.  
8.6 Final  Study  Visit  
A final study visit will  be performed for all participants  who began study treatment,  regardless  of whether  or not they  
entered  or completed the 24 week  treatment  course.  The final  visit will include:  
• Final  physical  exam  
• Blood  draw  
• Spi[INVESTIGATOR_038]  
• Pregnancy test  (females  only)  
 
Participants  recording only mild or  no symptoms  at the last office  visit will be discharged from the  study.  Participants  
recording  moderate  or severe  symptoms  at the last office  visit will require  follow -up as  described in 12, Safety  
Monitoring and Reporting.  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  23 of 37  
  
8.7 Early  Termination Visit  
Participants  may withdraw  or be dropped from  the study  during or between study  visits,  according to the criteria  in 
Section  11.2,  Participant  Stoppi[INVESTIGATOR_512032]. For participants  who withdraw  or are dropped during  
a study visit,  the visit will be terminated.  The study  clinician  will perform  a final  clinical  assessment,  including blood  
collection  and a targeted physical  exam,  as described in Section 8.6. 
Participants  who  withdraw  or are dropped from  the study  between  visits  will be contact[CONTACT_512059] a final  asse ssment  as described in Section  8.6 above.  For participants  who refuse  to 
come  to the clinic,  the final  clinical  assessment  as described above  may  be conducted over  the phone. Besides this  
visit,  no further follow -up will  be made,  except for participants  who  are discontinued due  to pregnancy or SAEs.  These  
participants  will be contact[CONTACT_512060].  Refer  to Section 12.6,  Pregnancy  
Reporting,  for more  information  on AE reporting  for pregnancy.  
8.8 Pregnancy  Visit  
Females  who  become  pregnant  during the  study will  be discontinued immediately  and no further  study  procedures  
will be performed.  These  participants  will be followed  to determine  the outcome  of the pregnancy; otherwise  no 
further  follow -up will be made.  
8.[ADDRESS_662318]  2 days.  Dose  escalation  may  be 
accomplished  over  a maximum of 18 weeks.  
Bi-weekly maintenance  visits  will be scheduled  within  the second  calendar  week  following the  previous  maintenance  
visit. See the MOP for details  regarding visit  scheduling.  
 
 
9 Mechanistic  Assays  
Whole  blood will  be collected by [CONTACT_512061],  and will  be processed  
according to the  MOP.  The blood  will be tested for  biomarkers  of allergen immunotherapy,  such as mouse -specific  IgE, 
IgG, IgG4  antibodies,  and in -vitro mouse  antigen binding  to B-cells  (see Appendix  A). 
 
 
10 Biospecimen  Storage  
Unused samples  of biological  specimens  (blood)  collected  during the  course  of the study will  be stored  (described in  
the MOP)  for future  use for tests  that may or may  not be planned.  These  tests  may  or may  not be related  to the study  
of asthma  and allergy. Participants  will be asked to  give permission for  long -term  storage  and future  use during  the 
consent  process.  Samples  may  be stored indefinitely.  
 
 
 
[ADDRESS_662319]  completed the  Final  Study  Visit.  
 
11.2 Participant  Stoppi[INVESTIGATOR_512033]:  
 
1. SAE related to  investigational agent  
2. Anaphylactic  reaction grade  2 or 3 (see Section  12.3.2,  Grading Criteria  for Anaphylaxis ) 
3. Inability  to tolerate the  build up to or the MSD  due to excessive  discomfort/symptoms  or large  local  reactions  
after  a second attempt  at dose  escalation  
4. The need  to start  immunotherapy or any chronic  immunosuppressive  medications  (e.g.,  greater than 2 courses  
of oral or parenteral  corticosteroids)  
5. Require  a dose  of greater than [ADDRESS_662320] of the participant  
8. Participant  is “lost  to follow -up,”  as defined in  the MOP  
9. Pregnancy  
10. A lapse  in dosing of more  than 3 weeks  during escalation  
11. Missing  more  than 2 consecutive  treatment visits  during maintenance  
12. Missing  25%  or more  of all maintenance  visits  (miss  more  than  2 maintenance  visits)  
 
11.3 Participant  Replacement  
Participants  who  withdraw  or are withdrawn will  be replaced until  the desired  sample  size is reached.  
 
11.4 Follow -up after Early  Study  Withdrawal  
Participants  who  withdraw  from the study after  receiving dose  1 will be followed  as described in  Section 6.5 
Premature  Discontinuation  of Investigational  Agent.  
11.5 Study  Stoppi[INVESTIGATOR_512034]: 
1. 1 death  regardless  of relationship to the investigational  agent  
2. 1 anaphylactic  reaction grade  3 (see Section  12.3.2,  Grading  Criteria for Anaphylaxis ) possibly  related  to the 
investigational  agent  
3. Either  of the following events,  which are  considered related  to the study  procedures  or treatments,  in at least  
2 participants : 
a. Anaphylactic  reactio n grade  2 (see Section 12.3.2,  Grading  Criteria for Anaphylaxis ). 
b. Hypotensive  shock:  Drop  in blood  pressure:  Systolic  < 90 mm Hg or < 80%  of baseline,  whichever  is 
higher,  and diastolic  blood  pressure  < 60 mm  Hg-absolute. 
If the study  is stopped due to meeting the  above  criteria,  it may  not be resumed until  all pertinent  information is  
discussed with DAIT  NIAID,  NIAID  Asthma  and Allergy  DSMB,  and the  site IRBs,  and all parties  concur  with the  
resumption  of the study.  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  25 of 37  
  
The study may  be terminated by [CONTACT_73884]/NIAID or the NIAID  DSMB  upon review  of any observations,  events,  or new  
information  that merit  such action.  
 
 
[ADDRESS_662321]  be reported promptly  (per Section  12.5,  Reporting  of Serious  Adverse  
Events  and Adverse  Events ) to DAIT/NIAID. Appropriate  notifications  will also be made  to site principal  investigators,  
and to the Institutional  Review  Boards  (IRBs).  
Information in  this section  complies  with ICH Guideline  E2A:  Clinical  Safety Data Management:  Definitions  and 
Standards  for Expedited Reporting,  ICH Guideline  E-6: Guideline  for Good  Clinical Practice,  21CFR  Parts  312 and 320,  
and applies  the standards  set forth in the  National Cancer  Institute (NCI),  Common  Terminology  Criteria for Adverse  
Events  (CTCAE), Version  4.03,  June  14, 2010:  http://ctep.cancer.gov/reporting/ctc.html . 
 
12.2 Definitions  
 
12.2.1 Adverse Event  (AE) 
An adverse  event  is any untoward or unfavorable  medical  occurrence  associated with the subject’s  participation in the 
research, whether  or not considered related to  the subject’s  participation in the  research  (modified from  the  
definition  of adverse  events  in the  1996 International  Conference  on Harmonization E-6 Guidelines  for Good  Clinical  
Practice)  (from OHRP "Guidance  on Reviewing and  Reporting Unanticipated Problems  Involving Risks  to Subjects  or 
Others  and Adverse  Events  (1/15/07)"  (http://www.hhs.gov/ohrp/policy/advevntguid.html#Q2  ) 
 
For this study,  a related adverse  events  will include  any untoward  or unfavorable  medical  occurrence  associated with:  
 
Study  therapy  regimen: Mouse  Allergenic  Extract  Administered by [CONTACT_512062]  
 
• Eye symptoms  (itchy,  runny,  swelling)  
• Nose  symptoms  (sneezing,  itching,  runny,  stuffy)  
• Mouth/ears/throat  symptoms  (itchy mouth,  throat  irritation,  oral or throat  angioedema,  cough,  
itchy  ears)  
• Skin symptoms  (angioedema,  urticaria,  generalized itching,  rash)  
• Gastrointestinal  symptoms  (vomiting,  diarrhea,  cramps,  nausea)  
• Chest  (cough,  tightness,  wheezing)  
• Anaphylaxis  
• Injection  site reaction  ≥ 6 cm in diameter 
 
 
Study  mandated procedures:  
Allergen Scratch  Skin Testing  
• Prolonged (>24  hours)  itching at  test site 
• Swelling (> 10 cm ) at site of test lasting  more  than 24 hours  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  26 of 37  
  
• Nasal allergic  symptoms  within 30 minutes of the procedure  
• Fainting/Vasovagal  event  within 30 minutes  of the procedure  
• Anaphylaxis  
 
Blood  Draws  
 
• Fainting/Vasovagal  events  
• Bruising at  puncture  site larger  than 2 cm diameter  
• Bleeding from  puncture  site lasting  more  than  30 minutes  
• Swelling at  puncture  site larger than 2 cm 
 
Pulmonary  Function  Testing  
 
• Wheezing or bronchoconstriction requiring treatment  with bronchodilators  within 30 minutes  
from the  procedure  
• Coughing requiring treatment  with bronchodilators  within 30 minutes  from the  procedure  
 
 
12.2.2 Suspected Adverse Reaction (SAR)  
Suspected adverse  reaction  (SAR)  means  any adverse event  for which there  is a reasonable  possibility  that the 
investigational  study  therapy  regimen  caused the  adverse  event.  For the purposes  of safety reporting,  ‘reasonable  
possibility’  means  there is evidence  to suggest  a causal relationship between the drug and the  adverse  event.  A 
suspected adverse  reaction  implies  a lesser  degree  of certainty  about  causality than adverse  reaction,  which  means  
any adverse  event  caused  by a drug (21  CFR 312.32(a)).  
 
12.2.3 Unexpected Adverse Event  
An adverse  event  or suspected adverse reaction is  considered  “unexpected” if  it is not listed in  the safety  information  
of Greer’s  package  insert  for allergenic  extracts  or is  not listed at  the specificity,  severity or rate of occurrence  that 
has been  observed; or is not consistent  with  the risk information  described  in the protocol. 
“Unexpected” also refers  to adverse  events  or suspected adverse  reactions  that are mentioned in the package  insert  
as occurring with a class  of drugs  or as  anticipated  from  the pharmacological properties  of the drug,  but are not 
specifically  mentioned as  occurring with the particular drug under  investigation  (21 CFR 312.32(a).  
 
12.2.4 Serious  Adverse  Event  (SAE)  
An adverse  event  or suspected adverse reaction is  considered  “serious” if,  in the view  of either  the investigator  or 
DAIT/NIAID,  it results  in any  of the following  outcomes  (21 CFR 312.32(a)): 
1. Death:  A d eath that  occurs  during the  study or that comes  to the attention  of the investigator  during the  
protocol -defined follow -up period  must  be reported  whether  it is considered treatment  related  or not. 
2. A life-threatening event:  An AE or SAR is considered “life -threatening”  if, in the view of either  the 
investigator  or DAIT/NIAID,  its occurrence  places  the subject  at immediate  risk of death.  It does  not 
include  an AE  or SAR that,  had it  occurred in a more  severe  form,  might  have  caused death.  
3. Inpatient  hospi[INVESTIGATOR_224633].  
4. Persistent  or significant  incapacity or substantial  disruption  of the ability to conduct  normal  life functions.  
5. Congenital  anomaly  or birth  defect.  
Version  2.[ADDRESS_662322]  of protocol  mandated procedures  are not 
to be reported  as an SAE  unless  hospi[INVESTIGATOR_512035]. 
12.3 Grading and Attribution of  Adverse Events  
 
12.3.1 Grading Criteria  
The study  site will grade  the severity of adverse  events  experienced by [CONTACT_512063]’s  Common Terminology Criteria  for Adverse  Events  (CTCAE) (Version 4.03,  June  
14, 2010).  This document  (referred  to herein as the NCI-CTCAE  manual)  provides  a common language  to describe  
levels  of severity,  to analyze  and interpret  data,  and to  articulate  the clinical  significance  of all adverse  events.  The 
NCI-CTCAE  has been reviewed by [CONTACT_512064].  
Adverse  events  will be graded on a scale  from 1 to 5 according to  the following standards  in the  NCI-CTCAE  manual:  
Grade  1 = mild adverse  event.  
Grade  2 = moderate  adverse  event.  
Grade  3 = severe  and undesirable  adverse  event.  
Grade  4 = life-threatening  or disabling adverse  event.  
Grade  5 = death.  
For grading an abnormal  val ue or result of a clinical  or laboratory evaluation  (including,  but not limited  to, a 
radiograph,  an ultrasound,  an electrocardiogram  etc.), a treatment -emergent  adverse event  is defined as  an increase  
in grade  from  baseline  or from the  last post -baseline  value  that doesn’t  meet  grading criteria. Changes  in grade  from  
screening to  baseline will also be recorded as  adverse  events,  but are not treatment -emergent.  If a specific  event  or 
result  from a given clinical  or laboratory evaluation is  not included in the NCI-CTCAE  manual,  then an abnormal  result  
would be  considered an adverse  event  if changes  in therapy or monitoring are implemented  as a result  of the 
event/result.  
 
12.3.[ADDRESS_662323]. Simon  
Brown .23 
 
  
 
  
 
   
 
 
 
 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  28 of 37  
  
Table 12.3.2  Grading  System  of Severity of  Anaphylaxis  
 
Grade Defined By 
1. Mild  (skin  & subcutaneous  tissues,  GI, 
&/or  mild respi[INVESTIGATOR_696])  Flushing,  urticaria,  periorbital  or facial  angioedema; mild  
dyspnea,  wheeze  or upper  respi[INVESTIGATOR_23908]; mild  
abdominal  pain and/or  emesis 
2. Moderate  (mild symptoms  + features  
suggesting moderate  respi[INVESTIGATOR_696],  
cardiovascular  or GI symptoms)  Marked  dysphagia,  hoarseness,  and/or  stridor;  SOB,  
wheezing & retractions;  crampy  abdominal pain,  
recurrent  vomiting and/or  diarrhea;  and/or  mild  
dizziness 
3. Severe  (hypoxia,  hypotension,  or 
neurological compromise)  Cyanosis  or SpO2 < 92%  at any stage,  hypotension,  
confusion,  collapse,  loss of consciousness; or 
incontinence  
 
 
12.3.3 Attribution Definitions  
The relationship,  or attribution,  of an adverse  event  to study  procedure(s)  will initially  be determined by [CONTACT_512065]/SAE  paper  case  report  form.  Final  determination  of attribution for 
safety reporting will  be determined by  [CONTACT_73884]/NIAID .  The relationship of an adverse  event  to study procedures  will be 
determined using the  descriptors  and definitions  provided in Table  12.3.3.  
For additional  information  and a printable  version of the NCI-CTCAE  manual,  consult  the NCI-CTCAE  web  site:  
http://ctep.cancer.gov/reporting/ctc.html . 
 
Table  12.3.3  Attribution of Adverse  Events  
 
Code Descriptor Relationship  (to primary  investigational  product  and/or  
other  concurrent  mandated  study therapy  or study  
procedure) 
Unrelated  Category 
1 Unrelated The adverse  event  is clearly  not related. 
Related  Categories 
2 Possible The adverse  event  has a reasonable  possibility  to be 
related;  there  is evidence to suggest  a causal  relationship.  
3 Definite The adverse  event  is clearly  related. 
 
 
12.4 Collection and Recording of  Adverse Events  
Adverse  events  (including SAEs)  will be collected from  the time  of consent  until  a subject completes  study    
participation  or until  30 days  after  he/she  prematurely  withdraws  (without  withdrawing  consent)  or is withdrawn from  
the study.  
 
12.4.1 Collecting Adverse Events  
Adverse  events  (including SAEs)  may  be discovered  through any of these methods:  
 
• Observing  the participant.  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  29 of 37  
  
• Interviewing the  participant. 
• Receiving an unsolicited complaint  from  the participant. 
• In addition,  an abnormal  value  or result  from  a clinical  or laboratory  evaluation  can also  indicate  an adverse  
event,  as defined in Section 12.3,  Grading and Attribution  of Adverse  Events . 
 
12.4.[ADDRESS_662324]  adverse  events  and serious  adverse  events  as described 
previously  (Section 12.2,  Definitions ) on the appropriate  AE/SAE  eCRF  regardless  of the relationship to study  
procedure.  
Once  recorded,  an AE/SAE  will be followed until  it resolves  with  or without  sequelae,  or until  the end of study  
participation,  or until  [ADDRESS_662325]  prematurely  withdraws  (without  withdrawing consent)/or  is withdrawn  
from the  study,  whichever  occurs  first.  
12.5 Reporting  of Serious  Adverse Events  and Adverse  Events  
 
12.5.1 Reporting  of Serious Adverse Events  to DAIT/NIAID  
This section describes  the responsibilities  of the site investigator to report  serious  adverse  events  to the sponsor  via 
the SAE CRF. Timely reporting of adverse  events  is required by  21 CFR and ICH E6 guidelines. 
Site investigators  will report  to the SACCC  (Rho,  Inc.)  and DAIT/NIAID  all serious  adverse  events  (see Section 12.2.4,  
Serious  Adverse  Event  (SAE) ), regardless  of relationship or expectedness  within 24 hours  of discovering  the event.  
For serious  adv erse events,  all requested information  on the AE/SAE  eCRF  will be provided.   However,  unavailable  
details  of the event  will not delay  submission  of the known information.  As additional  details  become  available,  the 
AE/SAE  eCRF  will be updated and submitted.  Every  time  the SAE eCRF is submitted,  it should be  signed by  [CONTACT_1275].  
For additional  information  regarding SAE  reporting,  contact  [CONTACT_512066]:  
Rho Product  Safety  
[ADDRESS_662326] 
Chapel  Hill, NC [ZIP_CODE] 
Toll-free: 1 -888- 746- 7231  
SAE Fax Line: 1 -[PHONE_1900] 
Email: [EMAIL_305]  
 
12.5.2 Reporting to Health Authority  
This study will  be conducted  with an IND exemption;  therefore  no health  authority  reporting  will be required.  Annual  
and expedited  reported,  as described below,  will be submitted  to the DSMB  and IRB, as appropriate.  
[IP_ADDRESS]  Annual  Reporting  
DAIT/NIAID  will include  in the  annual  study  report  all adverse  events  classified  as: 
 
• Serious,  expected,  suspected adverse  reactions  (see Section 12.2.2,  Suspected Adverse  Reaction (SAR), and 
Section  12.2.3,  Unexpected Adverse  Event ). 
• Serious  and not  a suspected adverse  reaction (see  Section  12.2.2,  Suspected Adverse  Reaction (SAR) ). 
 
 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  30 of 37  
  
• Pregnancies  not reported  as serious  adverse  events.  
 
Note  that all adverse  events  (not just those  requiring  24-hour  reporting)  will be reported annually.  
 
[IP_ADDRESS]  Expedited Safety  Reporting  
This option,  with  2 possible  categories,  applies  if the adverse  event  is classified as  one of the following:  
 
Category  1:  Serious  and unexpected suspected adverse reaction [S[LOCATION_003]R]  (see Section 12.2.2,  
Suspected Adverse  Reaction (SAR), and Section 12.2.3,  Unexpected Adverse  Event  and 21  CFR 
312.32(c)(1)i).  
The sponsor  must  report  any suspected adverse  reaction that  is both  serious  and unexpected.  The DAIT/NIAID must  
report  an adverse  event  as a suspected adverse  reaction only  if there  is evidence  to suggest  a causal  relationship  
between the  study drug and the  adverse  event,  such as:  
1. A single  occurrence  of an event  that is uncommon  and known  to be strongly  associated with  drug exposure  
(e.g.,  Grade  3 anaphylaxis  as described in  Table  12.3.2);  
2. One or more  occurrences  of an event  that is not commonly  associated  with drug exposure,  but is otherwise  
uncommon in the  population exposed to the drug (e.g.,  tendon rupture);  
3. An aggregate  analysis  of specific  events  observed in a clinical  trial (such as  known consequences  of the 
underlying disease  or condition under  investigation  or other  events  that commonly  occur  in the  study  
population independent  of drug therapy)  that indicates  those  events  occur  more  frequently  in the  
drug treatment group than  in a concurrent  or historical control  group.  
Category  2: Any fi ndings  from  studies  that  suggests  a significant  human risk  
 
The sponsor  must  report  any findings  from other  epi[INVESTIGATOR_101322],  analyses  of adverse  events  within the 
current  study  or pooled analysis  across  clinical studies  or animal or in vitro  testing (e.g.  mutagenicity,  teratogenicity,  
carcinogenicity)  that suggest a significant  risk in humans  exposed to the drug that  would result  in a safety -related  
change  in the  protocol,  informed consent,  investigator brochure  or package  insert  or other  aspects  of the overall  
conduct  of the study.  
DAIT/NIAID must  notify the  DSMB,  central  IRB, and all participating investigators  of expedited  Safety  Reports  within  15 
calendar  days;  unexpected  fatal  or immediately  life-threatening suspected adverse  reaction(s)  shall  be reported as  
soon  as possible  or within  [ADDRESS_662327]  shall  continue  
until  the conclusion of the pregnancy.  
The investigator shall report  to the Statistical  and Clinical Coordinating Center  (SACCC)  and DAIT/NIAID all  pregnancies  
within [ADDRESS_662328]  be reported.  The Pregnancy eCRF  shall  be  
updated and submitted to the  Statistical  and Clinical  Coordinating Center  (SACCC) when details  about  the outcome  are 
available. 
 
Information requested about  the delivery  shall  include:  
 
• Gestational age at delivery  
• Birth weight,  length,  and head  circumference  
• Gender  
• Appearance,  pulse,  grimace,  activity,  and respi[INVESTIGATOR_1516] (APGAR)  score  at 1 minute,  5 minutes,  and 24  hours  after 
birth,  if available  
• Any abnormalities. 
 
Should the  pregnancy  result  in a congenital  abnormality  or birth defect,  an SAE must  be submitted to  the Statistical  
and Clinical Coordinating Center  (SACCC)  and DAIT/NIAID  using the  SAE reporting  procedures  described above.  
12.7 Reporting  of Other  Safety Information  
An investigator shall  promptly  notify the  site IRB as well as the SACCC  and DAIT/NIAID  via email  when an 
“unanticipated problem  involving risks  to subjects  or others”  is identified,  which is not otherwise reportable  as an 
adverse  event.  
12.8 Review  of Safety Information  
 
12.8.1 Medical  Monitor  Review  
The DAIT/NIAID Medical  Monitor  shall  receive  monthly  reports  from  the SACCC  compi[INVESTIGATOR_512036], SAEs,  and pregnancies  recorded  by [CONTACT_3452](s)  on appropriate  paper  CRFs.  
In addition,  the Medical  Monitor  shall  review  and make decisions  on the disposition of the SAE and pregnancy  reports  
received by [CONTACT_512067]  (See  Section s 12.5.1,  Reporting  o f Serious  Adverse  Events  to DAIT/NIAID  and 12.6,  Pregnancy  
Reporting ). 
 
12.8.2 DSMB  Review  
The SACCC  will provide  the DSMB  with listings  of all SAEs  on an ongoing  basis,  including quarterly  reports  of all SAEs.  
Furthermore,  the DSMB  will be informed  of expedited  reports  of SAEs. 
[IP_ADDRESS] Planned DSMB  Reviews  
The NIAID  Asthma  and Allergy  Data  Safety and Monitoring Committee  (DSMB)  shall review  safety  data  at least  yearly  
during planned DSMB  Data Review  Meetings.  Data  for the planned safety  reviews  will include,  at a minimum,  a listing  
of all reported AEs  and SAEs.  
The DSMB  will be informed  of an  Expedited Safety  Report  in a timely manner.  An SAE which the  Medical  Monitor  
determines  to be an unexpected  safety  risk will be sent  to the DSMB  immediately. 
[IP_ADDRESS] Ad hoc DSMB  Reviews  
In addition to  the pre-scheduled data  reviews  and planned safety monitoring,  the DSMB  may  be called upon for ad hoc  
reviews.  The DSMB  will review  any event  that potentially  impacts  safety  at the request  of the protocol  chair  or 
DAIT/NIAID.  In addition,  any occurrence  of meeting one  of the study  stoppi[INVESTIGATOR_512037] 11.[ADDRESS_662329]  and/or  continuation.  
[IP_ADDRESS] Temporary  Suspension of Enrollment  and Drug Dosing  for ad hoc DSMB  Safety Review  
A temporary  halt in both  enrollment  and drug dosing will  be implemented if  an ad hoc DSMB  safety  review  is required. 
 
 
[ADDRESS_662330]  by [CONTACT_63275].  This is a phase  I safety  pi[INVESTIGATOR_512038]; thus,  only one analysis  
population,  the safety  population,  will be defined for this study.  The safety  population  will include  all study  
participants  who  receive  the initial  injection  during the  Dose  Initiation Visit. All statistical analyses  will be performed  
on the Safety Population.  
 
13.4.2 Primary Analysis  of Primary  Endpoint(s)/Outcome(s)  
The primary objective  of this pi[INVESTIGATOR_512039],  using the  per protocol  allergenic  
extract  doses,  is safe.  This will be done  by [CONTACT_512048].  Frequency of AEs and SAEs  will be tabulated by  [CONTACT_15992],  organ,  seriousness,  severity,  and 
treatment relatedness.  
 
13.4.[ADDRESS_662331]  95%  confidence  intervals  (Proc  
Freq,  SAS).  
Correlation analyses  will test for associations  between  baseline  allergy  diagnoses  (rhinitis,  asthma),  allergen  sensitivity  
(mouse -specific  IgE and IgG levels,  skin test  results),  and increased risk of AEs. Changes  from  baseline  levels  of mouse - 
specific  IgE, IgG, and IgG4  will be described in absolute  and relative  terms.  
 
13.4.4 Analyses  of Exploratory Endpoint(s)/Outcome(s)  
Not applicable.  
 
13.4.[ADDRESS_662332]  one event  given  
the sample  size of 280 injections  and the true event  rate.   For example,  if the true event  rate is 1%, the probability  that 
we observe  at least  one event  is 94%.  
 
Table 13.6  Probability of Observing Adverse  Events  According to  the “True”  Unknown Event  Rates  
 
“True” Unknown  Probability  of 
Event Probability  of 
Observing  at Least  
One Event*  
0.01% 2.7% 
0.05% 13.1% 
0.1 % 24.4 % 
0.5 % 75.4 % 
1 % 94.0 % 
5 % >99.9% 
10 % >99.9% 
25 % >99.9% 
50 % >99.9% 
 
 
* Assuming event  probabilities  are independent  both  within and between  participants.  Any correlation between  event  
probabilities  would reduce  the probability of seeing at  least  one event.  
Version  2.[ADDRESS_662333]  information,  visits  
consultations,  examinations  and other  information  are recorded.  Documentation of source  data  is necessary  for the 
reconstruction,  evaluation  and validation  of clinical findings,  observations  and other  activities  during a clinical  trial. 
14.2 Access  to Source Data  
The site investigators  and site staff  will make  all source  data available  to the DAIT/NIAID,  representatives  of the 
sponsor,  as well as to relevant  health authorities.  Authorized representatives  as noted  above  are bound to maintain 
the strict  confidentiality of medical  and research information that  may  be linked to identified individuals.  
 
 
[ADDRESS_662334]  the study in accordance  to the protocol; no  deviations  from  the protocol  
are permitted.   Any change,  divergence,  or departure  from the  study  design or procedures  constitutes  a protocol  
deviation.   As a result  of any deviation,  corrective  actions  will be developed by  [CONTACT_3483].  
 
15.1.2 Major  Protocol  Deviation (Protocol  Violation)  
A Protocol  Violation is  a deviation from the  IRB-approved protocol  that may  affect  the subject's  rights,  safety,  or well- 
being and/or  the completeness,  accuracy and reliability  of the study  data.   In addition,  protocol  violations  include  
willful  or knowing breaches  of human subject  protection regulations,  or policies,  any action that  is inconsistent  with  
the NIH Human  Research  Protection Program’s  researc h, medical,  and ethical  principles,  and a serious  or continuing 
noncompliance  with federal,  state,  local or institutional  human subject  protection  regulations,  policies,  or procedures.  
 
15.1.[ADDRESS_662335]'s  rights,  safety or well-being,  or the completeness,  
accuracy and reliability  of the study  data. 
15.[ADDRESS_662336]  review. 
Upon determination  that a protocol  deviation  (major or minor)  has occurred,  the study  staff  will a) notify the  PI, b) 
notify the  SACCC, and c) complete  the Protocol  Deviation form.  The Protocol  Deviation form  will document  at a 
minimu m the date  PD occurred,  the date  PD identified,  a description  of event,  whether  the deviation resulted in  
SAE/AE,  the signature  [CONTACT_39299], report  to IRB, and documentation  of a corrective  action plan.   The SACCC  and DAIT/NIAID  
may  request  discussion with  the PI [INVESTIGATOR_512040]/her  further study participation,  the effect  of the protocol  deviation on the overall  study,  and corrective  actions.  
The PI [INVESTIGATOR_512041], per IRB 
regulations. Major  protocol  deviations  will be reported to the DSMB  by [CONTACT_512068]’s  discretion.  
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  35 of 37  
  
16 Ethical  Considerations and Compliance  with  Good  Clinical Practice  
16.1 Statement  of Compliance 
This clinical  study  will be conducted using good clinical  practice  (GCP), as delineated in Guidance  for Industry:  E6 Good  
Clinical Practice  Consolidated Guidance , and according to the criteria  specified in  this study protocol.  Before  study  
initiation,  the protocol  and the informed  consent  documents  will be reviewed and approved by [CONTACT_512069]. Any 
amendments  to the protocol  or to the consent  materials  will also be approved by  [CONTACT_512070]. 
16.2 Informed Consent  Process 
The consent  process  will provide  information about  the study to a prospective  participant  and will allow  adequate  time  
for review  and discussion prior  to his/her  decision.  The principal investigator  [INVESTIGATOR_512042].  The consent  designee  must  be listed  on the delegation log,  have  
knowledge  of the study and received  training (from the  local  IRB, PI, or study  coordinator)  in the  consent  process   The 
prospective  participant  will be told that  being in the  trial is voluntary and that  he or she may withdraw  from the  study  
at any time,  for any reason.  All participants will read,  sign, and date  a consent  form  before  undergoing any  study  
procedures.  Consent  materials  will be presented in participants’  primary language.  A copy of the signed consent  form  
will be given to the  participant. 
The consent  form will  be revised  when important  new  safety information is  available,  the protocol  is amended,  and/or  
new  information becomes available  that may  affect  participation  in the  study.  
16.3 Privacy  and  Confidentiality  
A participant’s  privacy  and confidentiality will  be respected  throughout  the study.   Each  participant  will be assigned a 
unique  identification  number  and these  numbers  rather  than names  will be used  to collect,  store,  and report  
participant  information.  Site personnel  will not transmit  documents  containing personal  health identifiers  (PHI) to the  
study  sponsor  or their  representatives.  
 
 
17 Publication  Policy  
Presentations  and publication of the results  of this trial will be governed by  [CONTACT_512071].  
 
 
18 References  
1. Torjusen EN, Diette  GB, Breysse  PN, Curtin -Brosnan J,  Aloe  C, Matsui  EC. Dose -response  relationships  between  
mouse  allergen exposure  and asthma  morbidity among  urban children and adolescents.  Indoor  air 2013;23:[ADDRESS_662337], Breysse  PN, et al. Mouse  allergen  is the major  allergen  of public  health relevance  in 
Baltimore  City.  The Journal  of allergy  and clinical  immunology 2013;132:830 -5 e1-2. 
3. Matsui  EC. Environmental  exposures  and asthma  morbidity  in children living in urban neighborhoods.  Allergy  
2014;69:553- 8. 
4. Matsui  EC, Eggleston  PA, Buckley TJ,  et al. Household mouse  allergen exposure  and asthma  morbidity in inner - 
city preschool  children.  Annals  of allergy,  asthma  & immunology : official publication  of the American  College  of 
Allergy,  Asthma,  & Immunology  2006;97:[ADDRESS_662338]  sensitivity  in suburban,  middle -class  children  with asthma.  The Journal  of allergy  and clinical  immunology  
2004;113:910- 5. 
6. Matsui  EC,  Simons  E, Rand  C, et al. Airborne  mouse  allergen in the  homes  of inner -city children  with  asthma. 
The Journal  of allergy  and clinical immunology 2005;115:358 -63. 
Version  2.0 22 Jan 2016  
 Subcutaneous  Immunotherapy  for Mouse  Inner -City Asthma  Consortium  Confidential  Page  36 of 37  
  
7. Matsui  EC. Role  of mouse  allergens  in allergic  disease.  Current  allergy  and asthma  reports  2009;9:370 -5. 
8. Matsui  EC, Krop EJ,  Diette  GB, Aalberse  RC, Smith  AL, Eggleston  PA. Mouse  allergen exposure  and  
immunologic  responses:  IgE-mediated  mouse  sensitization and  mouse  specific  IgG and IgG4  levels.  Annals  of allergy,  
asthma  & immunology : official publication  of the American College  of Allergy,  Asthma,  & Immunology  2004;93:171 -8. 
9. Phipatanakul  W, Eggleston  PA, Wright  EC, Wood  RA. Mouse  allergen.  I. The prevalence  of mouse  allergen in  
inner -city homes.  The National  Cooperative  Inner -City Asthma  Study.  The Journal  of allergy  and clinical immunology  
2000;106:1070- 4. 
10. Phipatanakul  W, Eggleston PA, Wright  EC, Wood  RA. Mouse  allergen.  II. The relationship of mouse  allergen  
exposure  to mouse  sensitization and asthma morbidity  in inner -city children  with  asthma.  The Journal  of allergy  and 
clinical  immunology 2000;106:1075 -80. 
11. Allergen immunotherapy:  a practice  parameter second  update.  The Journal  of allergy  and clinical  immunology  
2007;120:S25 -85. 
12. Nelson HS.  Allergen immunotherapy: where  is it now? The  Journal  of allergy  and clinical immunology  
2007;119:769- 79. 
13. Nelson HS.  The use of standardized extracts  in allergen  immunotherapy.  The Journal  of allergy  and clinical 
immunology 2000;106:41 -5. 
14. Wahn U,  Siraganian RP. Efficacy  and specificity of immunotherapy with laboratory  animal allergen  extracts.  
The Journal  of allergy  and clinical immunology 1980;65:413 -21. 
15. Abramson  MJ , Puy RM, Weiner  JM. Is allergen immunotherapy  effective  in asthma? A meta -analysis  of 
randomized  controlled  trials.  American journal  of respi[INVESTIGATOR_297883]  1995;151:969 -74. 
16. Abramson  MJ, Puy RM, Weiner  JM. Allergen immunotherapy  for asthma.  Cochrane  database  of systematic  
reviews  (Online)  2003:CD001186.  
17. Ross RN, Nelson HS,  Finegold I. Effectiveness  of specific  immunotherapy in the  treatment  of allergic  rhinitis: an  
analysis  of randomized,  prospective,  single - or double -blind,  placebo -controlled studies.  Clinical  therapeutics  
2000;22:342- 50. 
18. Ross RN, Nelson HS,  Finegold I. Effectiveness  of specific  immunotherapy in the  treatment  of asthma:  a meta - 
analysis  of prospective,  randomized,  double -blind,  placebo -controlled studies.  Clinical therapeutics  2000;22:329 -41. 
19. Tankersley MS,  Butler  KK, Butler  WK, Goetz DW.  Local  reactions  during allergen immunotherapy  do not 
require  dose  adjustment.  The Journal  of allergy  and clinical imm unology 2000;106:840 -3. 
20. Lockey  RF, Nicoara -Kasti  GL, Theodoropoulos  DS, Bukantz SC.  Systemic  reactions  and fatalities  associated with  
allergen immunotherapy.  Annals  of allergy,  asthma  & immunology : official publication  of the American  College  of 
Allergy,  Asthma,  & Immunology  2001;87:47 -55. 
21. Malling HJ. Minimising the  risks  of allergen -specific  injection immunotherapy.  Drug Saf  2000;23:323 -32. 
22. Wood RA,  Togias  A, Wildfire  J, et al. Development  of cockroach immunotherapy by  [CONTACT_512072] -City Asthma  
Consortium.  The Journal  of allergy  and clinical  immunology  2013.  
23. Brown SG.  Clinical features  and severity  grading of anaphylaxis. The Journal  of allergy  and clinical  immunology  
2004;114:371- 6. 
 
 Inner -City Asthma  Consortium  Confidential  Page  37 of 37 
 
Appendix  A: Schedule  of Procedures/Evaluations  
 
 
 
Visit Number  
 
Screening   
 
Dose Initiation Bi-Weekly Dose 
Escalation  
Visits Bi-Monthly  
Maintenance  
Visits  
 
Final Visit 
Informed  consent,  screening X     
Medical  history X     
Physical  exam1 X X X X X 
Vital signs2 X X X X X 
Flu vaccine6 X     
Spi[INVESTIGATOR_038]  X    X 
Peak  flow X X X X X 
Adverse  event  assessment   X X X X 
Symptom  questionnaires  X X X X X 
Allergen  skin test X     
Blood  collection3 X X  X X 
Pregnancy  test4 X X X X X 
Dose escalation5  X X   
Injection  X X X  
 
 
[ADDRESS_662339]  not already  received  the vaccine.  
 
  
 
 
 
 
Subcutaneous  Immunotherapy  for Mouse  Version  2.0 22 Jan 2016 